Back to Search
MAANASI SAMANT, MD
MD
Pulmonary Disease Physician
NPI: 1427463074IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
2018007773(MO)
Critical Care Medicine (Internal Medicine) Physician
Internal Medicine — Critical Care Medicine
Code: 207RC0200X
2018007773(MO)
Pulmonary Disease PhysicianPrimary
Internal Medicine — Pulmonary Disease
Code: 207RP1001X
2018007773(MO)036157776(IL)
Education
UNIVERSITY OF TENNESSEE, HSC, COLLEGE OF MEDICINE
Class of 2014
Research & Publications (20)
Totally tubeless outpatient percutaneous nephrolithotomy: initial case report.
PMID 19478955·Adv Urol·2009
5-case
Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.
PMID 19224857·J Clin Oncol·2009
3-trial
Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis.
PMID 19053149·Eur J Immunol·2009
7-preclinical
Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
PMID 19542458·J Immunol·2009
7-preclinical
Ring size of somatostatin analogues (ODT-8) modulates receptor selectivity and binding affinity.
PMID 18410084·J Med Chem·2008
7-preclinical
Evaluation of antileishmanial potential of Tinospora sinensis against experimental visceral leishmaniasis.
PMID 18080140·Parasitol Res·2008
7-preclinical
Ring size in octreotide amide modulates differently agonist versus antagonist binding affinity and selectivity.
PMID 18410083·J Med Chem·2008
8-other
Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics.
PMID 18991606·Curr Drug Targets·2008
6-review
Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.
PMID 18762224·Vaccine·2008
7-preclinical
Antileishmanial activity mediated by apoptosis and structure-based target study of peganine hydrochloride dihydrate: an approach for rational drug design.
PMID 18694906·J Antimicrob Chemother·2008
7-preclinical
Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa.
PMID 18656517·Vaccine·2008
7-preclinical
Synthesis of protected norcysteines for SPPS compatible with Fmoc-strategy.
PMID 19562100·Tetrahedron Lett·2007
8-other
Age-influenced population kinetics and immunological responses of Leishmania donovani in hamsters.
PMID 17484071·Parasitol Res·2007
7-preclinical
Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.
PMID 17402723·J Med Chem·2007
7-preclinical
Proteophosphoglycan is differentially expressed in sodium stibogluconate-sensitive and resistant Indian clinical isolates of Leishmania donovani.
PMID 17362540·Parasitology·2007
7-preclinical
In vitro and in vivo leishmanicidal activity of Dysoxylum binectariferum and its fractions against Leishmania donovani.
PMID 17190644·Phytomedicine·2007
7-preclinical
Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
PMID 16759096·J Med Chem·2006
7-preclinical
Norcystine, a new tool for the study of the structure-activity relationship of peptides.
PMID 16706526·Org Lett·2006
8-other
Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.
PMID 16033265·J Med Chem·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 676 N SAINT CLAIR ST STE 2100
CHICAGO, IL 60611 - Phone
- (312) 695-1800
Quick Facts
- NPI
- 1427463074
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 4
- Locations
- 2
- Years in Practice
- 12
- Publications
- 20
Are you this provider?
Claim Your Profile